CIK 0001425205 · Accelerated filer
IOVANCE BIOTHERAPEUTICS, INC.
Sign in to watch- Ticker
- IOVA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 753254381
- Phone
- 6502607120
- Business address
- 825 INDUSTRIAL ROAD, 4TH FLOOR, SAN CARLOS, CA, 94070
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-02 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise · Restricted Stock Units | −3,906 | 11,720 | ||
| 2025-06-02 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Option exercise · Restricted Stock Units | −8,789 | 61,528 | ||
| 2025-06-02 | BILINSKY IGOR Chief Operating Officer | Option exercise | +12,305 | 99,883 | ||
| 2025-06-02 | BILINSKY IGOR Chief Operating Officer | Shares withheld for taxes | −6,250 | $1.76 | $11K | 93,633 |
| 2025-06-02 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −3,516 | 10,549 | ||
| 2025-06-02 | BILINSKY IGOR Chief Operating Officer | Option exercise · Restricted Stock Units | −8,789 | 61,528 | ||
| 2025-06-02 | Bellemin Jean-Marc Chief Financial Officer | Option exercise | +8,789 | 64,993 | ||
| 2025-06-02 | Bellemin Jean-Marc Chief Financial Officer | Shares withheld for taxes | −4,464 | $1.76 | $8K | 60,529 |
| 2025-06-02 | Bellemin Jean-Marc Chief Financial Officer | Option exercise · Restricted Stock Units | −8,789 | 61,528 | ||
| 2025-05-23 | Puri Raj K. Chief Regulatory Officer | Purchase | +5,600 | $1.74 | $10K | 206,852 |
| 2025-05-14 | Vogt Frederick G Interim CEO & General Counsel | Purchase | +25,000 | $1.69 | $42K | 374,646 |
| 2025-03-14 | Puri Raj K. Chief Regulatory Officer | Option exercise | +8,334 | 203,761 | ||
| 2025-03-14 | Puri Raj K. Chief Regulatory Officer | Shares withheld for taxes | −2,509 | $3.59 | $9K | 201,252 |
| 2025-03-14 | Puri Raj K. Chief Regulatory Officer | Option exercise · Restricted Stock Units | −8,334 | 0 | ||
| 2025-03-05 | Vogt Frederick G Interim CEO & General Counsel | Grant or award · Restricted Stock Units | +187,500 | 187,500 | ||
| 2025-03-05 | Puri Raj K. Chief Regulatory Officer | Grant or award · Restricted Stock Units | +117,190 | 117,190 | ||
| 2025-03-05 | GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer | Grant or award · Restricted Stock Units | +93,750 | 93,750 | ||
| 2025-03-05 | BILINSKY IGOR Chief Operating Officer | Grant or award · Restricted Stock Units | +93,750 | 93,750 | ||
| 2025-03-05 | Bellemin Jean-Marc Chief Financial Officer | Grant or award · Restricted Stock Units | +93,750 | 93,750 | ||
| 2025-03-03 | Bellemin Jean-Marc Chief Financial Officer | Option exercise | +58,590 | 87,938 |
Page 9 of 14 · 280 trades